|
WO2020163325A1
|
|
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
WO2020146902A2
|
|
Anti-variable muc1* antibodies and uses thereof
|
|
WO2019173815A2
|
|
Method for anti-muc1* car t cell stimulation
|
|
AU2019225237A1
|
|
Diagnostic methods using anti-MUC1* antibodies
|
|
WO2019126357A1
|
|
Agents for treating cancer and methods for identifying said agents
|
|
US2020390870A1
|
|
Humanized anti-muc1* antibodies and direct use of cleavage enzyme
|
|
EP3600451A1
|
|
Agents for differentiating stem cells and treating cancer
|
|
CN110267665A
|
|
The purposes of humanization anti-MUC1* antibody and nickase
|
|
AU2016326718A1
|
|
Method of screening for agents for differentiating stem cells
|
|
KR20180032583A
|
|
Method of stem cell-based organ and tissue generation
|
|
US2017106046A1
|
|
Method for diagnosing and treating cancer using naive state stem cell specific genes
|
|
WO2016130726A1
|
|
Humanized anti-muc1* antibodies
|
|
US2016326263A1
|
|
NME Inhibitors and Methods of Using NME Inhibitors
|
|
US2017204196A1
|
|
Anti-nme antibody
|
|
TW201529596A
|
|
Microbial NME
|
|
US2015218288A1
|
|
Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor
|
|
CN105764334A
|
|
Method for enhancing tumor growth
|
|
CN105229027A
|
|
The method of NME inhibitor and application NME inhibitor
|
|
EP2885000A2
|
|
Stem cell enhancing therapeutics
|
|
CN111849874A
|
|
NME variant species expression and inhibition
|
